Page 226 - Multidisipliner Covid 19

BÖLÜM 12

67. Xu X, Ong YK, Wang DY. Role of adjunctive treatment strategies in
COVID-19 and a review of international and national clinical guidelines.
Military Medical Research. 2020;7(22):1-18.https://doi.org/10.1186/
s40779-020-00251-x.
68. Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2- Mesenchymal
stem cells improves the outcome of patients with COVID-19 pneumonia.
Aging Dis. 2020;11(2):216–28.
69. Liang B, Chen J, Li T, et al., Clinical remission of a critically ill COVID-
19 patient treated by human umbilical cord mesenchymal stem cells.
ChinaXiv. 2020; 202002:00084.
70. Rosenberg ES, Dufort EM, Udo T, et al., Association of Treatment With
Hydroxychloroquine or Azithromycin With In-Hospital Mortality in
Patients With COVID-19 in New York State. JAMA. 2020; e208630. doi:
10.1001/jama.2020.8630
71. Ramireddy A, Chugh HS, Reinier K. et al., Experience with Hydroxychlo-
roquine and Azithromycin in the COVID-19 Pandemic: Implications
for QT Interval Monitoring. Medrxiv. https://doi.org/10.1101/2020.
04.22.20075671
72. Mercuro NJ, Yen CF, Shim DJ, et al., Risk of QT Interval Prolongation
Associated With Use of Hydroxychloroquine With or Without Concomi-
tant Azithromycin Among Hospitalized Patients Testing Positive for
Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020; e201834.
doi: 10.1001/jamacardio.2020.1834.
73. Hung IF-N, Lung K-C, Tso EY-K, et al., Triple combination of interferon
beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients
admitted to hospital with COVID-19: an open-label, randomised, phase
2 trial. Lancet. 2020; 395:1695-1704.
74. Zhu Z, Lu Z, Xu T, et al., Arbidol monotherapy is superior to lopinavir/
ritonavir in treating COVID-19. Journal of Infection. 2020; 10; S0163-
4453(20)30188-2. doi: 10.1016/j.jinf.2020.03.060.
75. Lian N, Xie H, Lin S, et al., Umifenovir treatment is not associated with
improved outcomes in patients with coronavirus disease 2019: a retro-
spective study. Clinical Microbiology and Infection. 2020; 25: S1198-743X
(20)30234-2. doi: 10.1016/j.cmi.2020.04.026.
76. Beigel JH, Tomashek KM, Lori E, et al., Remdesivir for the Treatment
of Covid-19-Preliminary Report. The New England Journal of Medicine.
2020; NEJMoa2007764. doi: 10.1056/NEJMoa2007764.

225